Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the CHEST ...
News Medical on MSN10d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...
Notably, GSK said it recently reduced the list price of Advair HFA by an average ... of those products and the rest of its ...
Qualcomm and its rival Propeller are emerging as the tech companies to partner with in the development of smart inhalers. Virtually all the companies active in the asthma and COPD markets have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results